California health centers asked Gov. Gavin Newsom (D) on Friday to delay implementing his controversial transfer of Medicaid drug benefits from managed care to fee for service until January 2022, to let health centers “focus on the needs of their
…
Category: Regulatory
Hikma Pharmaceuticals USA, the U.S. division of U.K.-based generic drug manufacturer Hikma Pharmaceuticals plc, is crediting 340B covered entities for overcharges on a long list of NDCs from the fourth quarter of 2017 through the fourth quarter of 2020.
The
…The generic drug manufacturer recently required to repay covered entities for charging above the ceiling price following an audit has posted a notice on the U.S. Health Services and Resources Administration (HRSA) website about recalculation of ceiling prices and “potential
…
Drug manufacturer Sanofi has exempted 11 of the 16 types of health care providers eligible to participate in the 340B program from its conditions on 340B pricing for its products dispensed by contract pharmacies. However, consolidated health center programs (CH),
…
USA Today, America’s top newspaper ranked by circulation, says claims circulating on social media that the Biden administration raised insulin prices by freezing a 340B-related Trump administration rule are “missing context.”
Last Friday, the national newspaper’s Fact Check feature
…
Forty-four New York state legislators have signed a letter to Gov. Andrew Cuomo (D) expressing “strong opposition” to the scheduled transfer in April of Medicaid managed care pharmacy benefits to Medicaid fee for service. They said the transfer “will have
…
Nearly all 340B-related program guidance documents have been taken down from an online database that the Trump administration launched last summer to underscore its position that federal government guidance documents are non-binding.
The U.S. Health Resources and Services Administration’s (HRSA)
…
The American Hospital Association (AHA) asked the Biden administration this week to immediately withdraw the Trump administration’s “most favored nation” (MFN) drug pricing interim final rule, in part, because of the damage it will do to 340B hospitals and “critical
…The U.S. Health Resources and Services Administration (HRSA) is requiring Pharmaceutical Associates, Inc. (PAI), a South Carolina-based generic liquid drug manufacturer, to repay 340B covered entities for charges on its products above the 340B ceiling price discovered during a fiscal
…Illinois-based Eton Pharmaceuticals is making its Alkindi Sprinkle hydrocortisone product available through a sole specialty distributor “to ensure that patients…receive appropriate drug and clinical counseling and to support therapeutic adherence,” the company informed 340B covered entities in a Jan. 12
…